When to stop immune checkpoint inhibitor for malignant melanoma? Challenges in emulating target trials
Prof
Université Paris Cité and Université Sorbonne Paris Nord
Event Information
Host
ICM Paris Brain Institute
Duration
70 minutes
Abstract
Observational data have become a popular source of evidence for causal effects when no randomized controlled trial exists, or to supplement information provided by those. In practice, a wide range of designs and analytical choices exist, and one recent approach relies on the target trial emulation framework. This framework is particularly well suited to mimic what could be obtained in a specific randomized controlled trial, while avoiding time-related selection biases. In this abstract, we present how this framework could be useful to emulate trials in malignant melanoma, and the challenges faced when planning such a study using longitudinal observational data from a cohort study. More specifically, two questions are envisaged: duration of immune checkpoint inhibitors, and trials comparing treatment strategies for BRAF V600-mutant patients (targeted therapy as 1st line, followed by immunotherapy as 2nd line, vs. immunotherapy as 2nd line followed by targeted therapy as 1st line). Using data from 1027 participants to the MELBASE cohort, we detail the results for the emulation of a trial where immune checkpoint inhibitor would be stopped at 6 months vs. continued, in patients in response or with stable disease.
Topics
Related Seminars
Mortality Displacement: Sixty Years of Debate and Consequences
Harvard T.H. Chan School of Public Health Department of Epidemiology seminar by David Jones, MD, PhD (Chair, Department of the History of Science, Harvard; Professor of Epidemiology) on the…
Dark Causal Inference: Why Most Causal Inference in Epidemiology is Invisible
Harvard T.H. Chan School of Public Health Department of Epidemiology seminar by Jeremy Labrecque, PhD, MSc (Assistant Professor of Epidemiology and Causal Inference, Erasmus MC, Rotterdam) on 'dark…
Related Job Opportunities
PhD Studentship: Mitochondrial Metabolism and Novel Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (Fixed Term)
Supervisors: Professor Andrew Murray, Department of Physiology, Development and Neuroscience, University of Cambridge Dr Ross Lindsay, Novo Nordisk Funding: Fully funded PhD studentship (Home/UK…
Research Associate (Fixed Term)
We seek a highly motivated Postdoctoral Research Associate to join the laboratory of Professor Kathy Niakan. We are based in the Loke Centre for Trophoblast Research (LCTR), in the Department of…
Research Assistant/Associate (Fixed Term)
Applications are invited for a postdoctoral research associate position to study the neural mechanisms of visual learning in mice, in the laboratories of Professor Ole Paulsen and Dr Jasper Poort…